Literature DB >> 34580037

Tumor mutational burden and immunotherapy in gliomas.

Mythili Merchant1, Alice Ranjan1, Ying Pang1, Guangyang Yu1, Olga Kim1, Javed Khan2, Jing Wu3.   

Abstract

Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression, and presentation. Published by Elsevier Inc.

Entities:  

Keywords:  gliomas; immunotherapy; neoantigens; tumor mutational burden

Mesh：

Substances：

Year:  2021        PMID： 34580037     DOI： 10.1016/j.trecan.2021.08.005

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  2 in total

Review 1.  Helicobacter pylori promotes gastric cancer progression through the tumor microenvironment.

Authors:  Linqi Zhu; Yue Huang; Hong Li; Shihe Shao
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-20       Impact factor: 4.813

2.  Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas.

Authors:  Guangyang Yu; Ying Pang; Mythili Merchant; Chimene Kesserwan; Vineela Gangalapudi; Abdalla Abdelmaksoud; Alice Ranjan; Olga Kim; Jun S Wei; Hsien-Chao Chou; Xinyu Wen; Sivasish Sindiri; Young K Song; Liqiang Xi; Rosandra N Kaplan; Terri S Armstrong; Mark R Gilbert; Kenneth Aldape; Javed Khan; Jing Wu
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.